ELDN

Eledon Pharmaceuticals Inc

Mar 24 • 04:00PM ET

2.89

-0.21 -6.77 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN AMGN GILD VRTX INCY ILMN ALNY BMRN NBIX

| Held by: VTI IWM VXF IWN VTWO IWC IWO RSSL VTWV DFAC

Index	RUT	P/E	-	EPS (ttm)	-0.59	Insider Own	5.28%	Shs Outstand	75.43M	Perf Week	0.35%
Market Cap	216.99M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	0.00%	Shs Float	71.12M	Perf Month	27.31%
Enterprise Value	139.98M	PEG	-	EPS next Q	-0.18	Inst Own	60.60%	Short Float	11.84%	Perf Quarter	76.22%
Income	-45.62M	P/S	-	EPS this Y	-64.62%	Inst Trans	12.03%	Short Ratio	8.66	Perf Half Y	11.15%
Sales	0.00M	P/B	2.69	EPS next Y	3.62%	ROA	-19.53%	Short Interest	8.42M	Perf YTD	91.39%
Book/sh	1.07	P/C	1.63	EPS next 5Y	-18.71%	ROE	-35.79%	52W High	4.60 -37.17%	Perf Year	-19.94%
Cash/sh	1.78	P/FCF	-	EPS past 3/5Y	55.10% 48.72%	ROIC	-33.28%	52W Low	1.35 114.07%	Perf 3Y	22.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.76% 8.53%	Perf 5Y	-76.25%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	61.62%	Oper. Margin	-	ATR (14)	0.22	Perf 10Y	-99.66%
Dividend Ex-Date	-	Quick Ratio	7.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.15	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.40	EPS Q/Q	81.44%	SMA20	5.30%	Beta	0.85	Target Price	7.80
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	21.36%	Rel Volume	1.41	Prev Close	3.10
Employees	33	LT Debt/Eq	0.00	Earnings	Mar 19 AMC	SMA200	12.53%	Avg Volume	972.18K	Price	2.89
IPO	Sep 17, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	38.51% -	Trades		Volume	1,366,651	Change	-6.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-25	Resumed	H.C. Wainwright	Buy	$9
Jan-28-25	Initiated	Guggenheim	Buy	$9
May-13-22	Resumed	Cantor Fitzgerald	Overweight	$25 → $15
Mar-23-21	Initiated	Cantor Fitzgerald	Overweight	$25

Mar-19-26 05:10PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results (GlobeNewswire) -5.00%
Mar-16-26 07:00AM	Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine (GlobeNewswire)
Mar-10-26 07:00AM	Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation (GlobeNewswire)
06:53AM	NewcelX and Eledon partner for NCEL-101 programme (Hospital Management)
Mar-04-26 04:05PM	Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
12:34PM	Loading…
Feb-13-26 12:34PM	Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for Tego at Conference (MarketBeat)
Feb-05-26 04:10PM	Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -8.37% +11.17%
Jan-23-26 07:00AM	Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium (GlobeNewswire)
Jan-08-26 04:05PM	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook (GlobeNewswire)
Dec-31-25 08:07AM	The End of Shots? 5 Biotech Stocks Rethinking Diabetes (PR Newswire)
Dec-01-25 07:00AM	Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire) -6.13%
Nov-18-25 04:05PM	Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine (GlobeNewswire)
Nov-14-25 05:00PM	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results (GlobeNewswire) -7.95%
Nov-12-25 07:56AM	Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -11.27%
Nov-11-25 05:26PM	Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.33%
06:30PM	Loading…
Nov-06-25 06:30PM	Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting (GlobeNewswire) -49.76%
Nov-05-25 07:00AM	Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-17-25 07:00AM	Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting (GlobeNewswire) +20.70%
Sep-24-25 04:05PM	Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association (GlobeNewswire) -5.10%
Sep-23-25 07:30AM	2 Strong Buy Stocks That Wall Street Believes Can Soar 360% to 780% (Barchart)
Aug-29-25 07:00AM	Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-14-25 04:20PM	Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results (GlobeNewswire)
Aug-06-25 04:01PM	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation (GlobeNewswire) +9.90% -20.20%
Jul-31-25 11:40PM	Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress (Insider Monkey) +7.30%
Jul-30-25 04:05PM	Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 (GlobeNewswire)
Jul-17-25 04:01PM	Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025 (GlobeNewswire)
Jul-14-25 10:00AM	Best Momentum Stocks to Buy for July 14th (Zacks) +14.33%
06:09AM	New Strong Buy Stocks for July 14th (Zacks)
Jul-09-25 08:30AM	Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes (GlobeNewswire)
Jun-25-25 04:01PM	Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City (GlobeNewswire)
12:00PM	Loading…
May-23-25 12:00PM	What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock (Zacks)
May-14-25 04:01PM	Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results (GlobeNewswire)
May-03-25 08:15AM	Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet (Seeking Alpha)
Mar-27-25 10:16AM	Is Eledon Pharmaceuticals (ELDN) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results (GlobeNewswire)
Mar-04-25 04:05PM	Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-07-25 10:00AM	Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human (GlobeNewswire)
Jan-29-25 04:05PM	Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 07:00AM	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook (GlobeNewswire)
Nov-12-24 04:01PM	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire) -11.41%
Nov-06-24 04:05PM	Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-29-24 07:46AM	Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.53%
07:45AM	Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine (GlobeNewswire)
Sep-11-24 04:05PM	Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-04-24 07:00AM	Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients (GlobeNewswire) -5.84%
Aug-14-24 05:21PM	Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results (GlobeNewswire)
Jul-29-24 07:00AM	Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection (GlobeNewswire)
Jul-02-24 04:05PM	Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire)
Jun-17-24 09:36AM	Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues (InvestorPlace) -6.93%
Jun-11-24 03:18PM	3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024 (InvestorPlace)
Jun-03-24 04:01PM	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation (GlobeNewswire)
May-27-24 09:55AM	Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-22-24 12:00PM	Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy? (Zacks)
May-14-24 12:00PM	Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.85%
May-09-24 01:54PM	ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
07:00AM	Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress (GlobeNewswire)
May-07-24 07:05AM	Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection (GlobeNewswire) -7.38%
07:00AM	Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement (GlobeNewswire)
Mar-28-24 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results (GlobeNewswire)
Mar-25-24 04:56PM	Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection (GlobeNewswire)
Mar-21-24 10:31AM	Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human (GlobeNewswire) +11.24%
Feb-13-24 07:01PM	Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-24 04:40PM	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook (GlobeNewswire)
Dec-04-23 06:00PM	Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.67%
Nov-29-23 04:05PM	Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference (GlobeNewswire) -6.67%
Nov-09-23 04:01PM	Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire)
Nov-08-23 04:05PM	Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-23 09:05AM	Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation (GlobeNewswire) -10.37%
Oct-23-23 07:00AM	Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer (GlobeNewswire)
Oct-13-23 07:00AM	Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting (GlobeNewswire)
Oct-02-23 07:00AM	Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors (GlobeNewswire) +13.14%
Sep-25-23 07:00AM	Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human (GlobeNewswire)
Sep-20-23 04:05PM	Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-11-23 07:00AM	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors (GlobeNewswire)
Sep-06-23 07:00AM	Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates (GlobeNewswire) -11.89%
Sep-05-23 07:00AM	Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation (GlobeNewswire)
Aug-16-23 07:00AM	Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation (GlobeNewswire)
Aug-10-23 07:00AM	Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Jul-12-23 07:30AM	Amerigo Reports Q2-2023 Production Results and Provides MVC Operational Update (GlobeNewswire)
Jun-02-23 08:00AM	Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:01PM	Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results (GlobeNewswire) -13.00%
May-04-23 04:05PM	Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (GlobeNewswire) +6.33% +6.35%
May-01-23 07:00AM	Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials (GlobeNewswire) +9.52%
Apr-05-23 07:46PM	Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:00AM	Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology (GlobeNewswire) -5.98%
Mar-30-23 04:01PM	Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results (GlobeNewswire) +5.91%
Mar-23-23 04:05PM	Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023 (GlobeNewswire) -8.05%
08:00AM	Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023 (GlobeNewswire)
Feb-08-23 04:05PM	Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-09-23 08:31AM	Eledon Pharmaceuticals Provides Business and Pipeline Updates (GlobeNewswire)
08:30AM	eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies (GlobeNewswire)
Dec-21-22 04:05PM	C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System (GlobeNewswire)
Nov-14-22 04:01PM	Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire) +8.30%
Nov-03-22 04:05PM	Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 (GlobeNewswire) -6.37%
Oct-24-22 04:05PM	Eledon Pharmaceuticals Announces Upcoming Presentations at ASNs Kidney Week 2022 and NEALS (GlobeNewswire)
Oct-03-22 08:00AM	Eledon Pharmaceuticals to Participate in Two Upcoming Conferences (GlobeNewswire)
Sep-22-22 04:05PM	Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference (GlobeNewswire) -7.93% -10.60%
Sep-06-22 04:01PM	Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy (GlobeNewswire)
Aug-29-22 08:00AM	Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The firm also focuses on development of therapy to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L), a biological target with broad therapeutic potential. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
McBride John S.	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM
Hillson Jan	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM
Kirk Allan	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM
Katkin Keith	Director	Jan 10 '26	Option Exercise	8,575	8,575	Jan 16 05:00 PM
Lee June	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM
Robinson James A. Jr.	Director	Jan 10 '26	Option Exercise	3,430	3,430	Jan 16 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELDN

Eledon Pharmaceuticals Inc

Upgrade your FINVIZ experience